Diabetes
Conditions
Brief summary
The study objectives are described below: 1. Obtain matched serum, plasma \[(K2 EDTA, Sodium Heparin (NaH), Lithium Heparin (LiH)\] and urine specimens collected from a minimum of 50 healthy subjects. Specimens will be used to determine a reference range for C-peptide and insulin assays, used as an aid in the assessment of C-peptide and insulin in adults. 2. Obtain serum and urine specimens collected from a minimum of an additional 200 healthy subjects. Specimens will be used to determine a reference range for C-peptide and insulin assays, used as an aid in the assessment of C-peptide and insulin in adults. 3. To store any remaining specimens for use in future assay development and to evaluate as yet undetermined assays for the development of IVDs, including additional C-peptide or insulin assays.
Detailed description
The primary object of this study is to obtain a series of blood and urine specimens from women and men who are healthy with no history of abnormal blood sugar levels. The specimens will be used to evaluate new C-peptide and insulin assays (tests). Participants are being asked to voluntarily take part in this study because they are a healthy individual without a history of abnormal blood sugar levels.
Interventions
OTHERProspective Blood Draw
This is prospective collection blood and urine study. This is not a treatment trial or device trial.
Sponsors
Fujirebio Diagnostics, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Males and females, age ≥ 18 years * Fasting for 12 hours prior to blood draw and random urine collection * Able to understand and willing to provide informed consent * Normal HbA1c (e.g. less than 5.7%) and glucose (e.g. less than 100 mg/dL) levels
Exclusion criteria
* Males and females, age \<18 years * Has a current diagnosis of any clinically significant cardiac, respiratory, neurological, immunological, hematological, liver disease, renal disease, gastrointestinal (GI) disorder, including any history of hyper- or hypothyroid, peptic or gastric ulcers or GI bleeding, or any other condition which, in the opinion of the investigator, would deem the subject unhealthy and therefore, ineligible. * Has a history of any clinically significant cardiac, respiratory, neurological, immunological, hematological, liver disease, renal disease, gastrointestinal (GI) disorder, including any history of hyper- or hypothyroid, peptic or gastric ulcers or GI bleeding, or any other condition which, in the opinion of the investigator, is unstable at the time of enrollment. * Current diagnosis or prior history of any type of diabetes including gestational diabetes. * Currently taking or history of insulin therapy for any disease. * Elevated HbA1c level (e.g. greater than 5.7%) * Elevated glucose level (e.g. greater than or equal to 100 mg/dL) * Is receiving systemic chemotherapy or radiation treatment, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before screening other than basal or squamous cell skin cancers or in-situ cervical cancer. * History of seizures * Diagnosed with an infectious disease including any sexually transmitted diseases. * Diagnosed with HIV/AIDS or ever tested positive for HIV. * History of hepatitis * Subject that has had sexual contact with a person who has hepatitis within the last 12 months. * Pregnancy or lactation * Non-fasting for 12 hours prior to blood and random urine collection. * Hemolytic blood specimen * Unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure C-peptide and Insulin in Healthy Individuals | 10 months | 250 healthy subjects |
Countries
United States
Outcome results
None listed